AstraZeneca Global Program

Activating at Risk Asthma Patients with Effective Patient Communication

Thys van der Molen & Pin-Kuei Fu

Tuesday, March 22, 2022  

6:00pm – 7:00pm  EST / 3:00 to 4:00 PST

Thys van der Molen

Professor Thys van der Molen retired as Professor of Primary Care Respiratory Medicine in Groningen, The Netherlands, and currently holds a position as Global Medical Expert for the General Practitioners Research Institute (GPRI) The Netherlands. His main research interests include: respiratory diseases (asthma and chronic obstructive pulmonary disease [COPD]), integrated care, and the development of outcome measures, symptom and diagnostic questionnaires. He developed the Clinical COPD Questionnaire (CCQ) (www.ccq.nl), which aims to measure health status in patients with COPD. He is the Founding President of the International Primary Care Respiratory Group (IPCRG), was a member of the GOLD executive Committee between 2002 and 2008, and he is a member of the local Dutch asthma COPD GP group (CAHAG). Finally, he is a member of the Dutch inhalation work group IRW.

Dr Pin-Kuei Fu

Dr Pin-Kuei Fu currently works in Taichung Veterans General Hospital (TCVGH). He is the  director of Respiratory Intensive Care Unit (R ICU) at TCVGH and associate Professor in Ph.D.  Program in Translational Medicine National Chung Hsing University . Dr Fu does research in  chronic respiratory tract diseases, such as COPD, interstitial lung disease and severe Asthma. In  the field of critical care, Dr. Fu does research in acute respiratory distress syndrome, fungal  infection (CPA and IPA), and clinical nutrition. He has 31 SC I publications during the past 3 years

KEY TOPICS:

-  Highlight the ‘disconnect’ and challenge of using the term ‘control’ with asthma patients and how the Reliever Reliance Test (RRT) and other tools could facilitate patient communication

- Communicate the scale of SABA over reliance showing a universal public health issue (SABINA study) 

-  Review the evidence base informing the GINA 2021 recommendation / National Guidelines and the change in preferred reliever from SABA to ICS-formoterol

*In case you cannot join the live session, the on-demand video will be available via the samelink as the live session 24 hours after the live event. Register for the live event to get access to the on-demand video

This event is organized and funded by AstraZeneca